miRNA-132 induces hepatic steatosis and hyperlipidaemia by synergistic multitarget suppression.

导出 OA

翻译打印收藏纠错

作者： Geula,Hanin ^[1] ; Nadav,Yayon ^[1] ; Yonat,Tzur ^[1] ; Rotem,Haviv ^[1] ; Estelle R,Bennett ^[1] ; Shiran,Udi ^[2] ; Yoganathan R,Krishnamoorthy ^[3] ; Eleni,Kotsiliti ^[4] ; Rivka,Zangen ^[1] ; Ben,Efron ^[1] ; Joseph,Tam ^[2] ; Orit,Pappo ^[5] ; Eyal,Shteyer ^[6] ; Eli,Pikarsky ^[3] ; Mathias,Heikenwalder ^[5] ; David S,Greenberg ^[4] ; Hermona,Soreq ^[7]

作者单位： The Silberman Institute of Life Sciences and the Edmond and Lily Safra Center for Brain Science, The Hebrew University of Jerusalem, Edmond J. Safra Campus, Jerusalem, Israel. ^[1] Obesity and Metabolism Laboratory, The Institute for Drug Research, School of Pharmacy, Faculty of Medicine, The Hebrew University of Jerusalem, Jerusalem, Israel. ^[2] The Lautenberg Center for Immunology and Cancer Research, Institute for Medical Research Israel Canada, Hebrew University-Hadassah Medical School, Jerusalem, Israel. ^[3] Institute of Virology, Technische Universität München and Helmholtz Zentrum München, Munich, Germany. ^[4] The Department of Pathology, Hadassah-Hebrew University Medical Center, Jerusalem, Israel. ^[5] The Juliet Keidan Institute of Pediatric Gastroenterology and Nutrition, Shaare Zedek Medical Center, Jerusalem, Israel. ^[6] Division of Chronic Inflammation and Cancer, German Cancer Research Center (DKFZ), Heidelberg, Germany. ^[7]

关键词 FATTY LIVER NONALCOHOLIC STEATOHEPATITIS